Using recombinant insulin in DoE for media development

In the culture of mammalian cells, the use of commercially available chemically defined media is common practice. These media are optimised to support cell growth and recombinant protein production and are usually highly complex. However, their composition is usually proprietary and unknown for the user. When used for a specific cell line, CD media may not support its specific requirements. Therefore, supplementation with other compounds at optimal concentrations may substantially improve cell performance.

In the presentation “Why Use Recombinant Insulin in DoE For Your Media Development?”, Product Manager Chantale Julien share a case study conducted in partnership with Universitat Autònoma de Barcelona. The experiment used a CHO cell line – the preferred mammalian cell host for the production of recombinant proteins, including monoclonal antibodies (mAbs).

Media supplementation is generally addressed by means of the traditional one-factor-at-a-time Design of Experiment (DoE) approach. However, these techniques may be inefficient, time-consuming and costly in the initial screening phases. In this study, a DoE statistical approach that used a combination of the Plackett-Burnham and Box-Behnken designs was deployed to increase cell growth and mAb production through supplementation with animal-free recombinant compounds.

You can read more and see the presentation here.

Recombinant Insulin
Get the latest insights in our new e-book.